Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / EVER Pharma - LARVOL DELTA

Efficacy and Safety of Cerebrolysin as an Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Observational Studies. (PubMed, Brain Behav) - "Cerebrolysin shows promise as a useful neuroprotective treatment in stroke care by dramatically improving functional recovery, reducing symptomatic intracranial bleeding, and lowering mortality in acute ischemic stroke patients when used in conjunction with mechanical thrombectomy. Nonetheless, these conclusions are derived from only three observational studies with small sample sizes, which limits the robustness and generalizability of the findings. Further large-scale randomized trials are warranted to confirm these effects."

Clinical • Journal • Observational data • Retrospective data • Review • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

Retraction Note: Neurotrophic effects of Cerebrolysin in the Mecp2308/Y transgenic model of Rett syndrome. (PubMed, Acta Neuropathol) - No abstract available

Journal • Developmental Disorders • Movement Disorders

The Role of Cerebrolysin in Promoting Axonal Regeneration and Functional Recovery after Peripheral Nerve Injury: A Focus on Macrophage Activation. (PubMed, Adv Pharm Bull) - "The 5 mg/kg dosage proved to be more effective than the 2.5 mg/kg dose. This study highlights the potential of Cerebrolysin as a therapeutic agent for peripheral nerve injuries."

Journal • Muscular Atrophy

The effect of Cerebrolysin on the development of skills in patients after acute cerebrovascular accidents (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova) - "The use of Cerebrolysin in a dose of 10 ml to 30 ml during post-stroke rehabilitation leads to an increase in the quantity and quality of restored functions and formed skills, which was shown in a small group of 10 studies."

Journal • Review • Cardiovascular • CNS Disorders • Depression • Psychiatry

The effect of neuroprotectors on the level of BDNF, tumor necrosis factor alpha and apoptosis markers, and in acute cerebrovascular accidents (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova) - "Thus, when administered at the onset of reperfusion following MCA occlusion, Mexidol exerts the most pronounced cerebroprotective effect, stimulating neurogenesis and suppressing the development of neuroinflammation and apoptosis."

Journal • Cardiovascular • Oncology • BAX • BDNF • CASP3 • TNFA

The Efficacy and Safety of Cerebrolysin on Functional Outcomes in Acute Ischemic Stroke: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials (AAN 2026) - "Cerebrolysin demonstrates potential benefits in reducing NIHSS scores, improving ARAT and BI as continuous outcomes, and enhancing upper limb FMA in later phases, with favorable trends in mRS and MMSE, though heterogeneity and non-significant effects in some dichotomous outcomes limit conclusions. Safety profiles were comparable to placebo, supporting its use as an adjunct in stroke rehabilitation."

Retrospective data • Review • Cardiovascular • Ischemic stroke

Cerebrolysin and Risk of Hemorrhagic Transformation: A Pooled Analysis of Recent Studies. (PubMed, J Clin Neurol) - No abstract available

Journal • Retrospective data • Hematological Disorders

Cerebrolysin after Endovascular Thrombectomy in Stroke: 12‑Month Functional Outcomes in a Propensity‑Matched Cohort. (PubMed, Transl Stroke Res) - "Conclusions In EVT-treated patients selected for a small infarct core, robust collaterals, and high-quality reperfusion, adjunctive Cerebrolysin showed a potential benefit toward better 12-month functional outcomes. These exploratory findings require confirmation in multicenter randomized trials to establish efficacy and refine patient selection."

Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

Comparative Efficacy of Interventions for Supratentorial Stroke: A Bayesian NMA with Meta-Regression (ISC 2026) - "Pharmacologic options (e.g., tranexamic acid, atorvastatin, cerebrolysin) showed no significant benefit for mortality or function compared with standard care. For acute supratentorial ICH, surgical approaches—especially minimally invasive endoscopic evacuation—yield superior 6-month survival and functional outcomes compared with medical therapy alone. Conventional craniotomy confers a moderate survival advantage. Pharmacologic adjuncts did not improve hard outcomes in this network."

Clinical • Cardiovascular

Experience of using of Cerebrolysin in comprehensive rehabilitation of a patient after ischemic stroke with motor deficit and aphasia (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova) - "Course administration of Cerebrolysin as part of a comprehensive rehabilitation program in a patient with motor deficit and complex motor aphasia after IS demonstrated a favorable safety profile and contributed to a significant improvement in both limb motor function and speech, which is consistent with the results of previous studies. The obtained results support the recommendation for the course-based use of Cerebrolysin in multidisciplinary neurorehabilitation programs to enhance neuroplasticity processes and improve functional outcomes."

Journal • Cardiovascular • Ischemic stroke

Cerebrolysin, hemorrhagic transformation, and anticoagulation timing after reperfusion therapy in stroke: post hoc secondary analysis of the CEREHETIS trial. (PubMed, Front Pharmacol) - "In IVT-treated MCA stroke patients with HTI 1-4, Cerebrolysin may reduce HT hazard and advance the risk-equilibrium point by approximately 1-2 days. These findings are preliminary and hypothesis-generating, suggesting that Cerebrolysin may allow earlier-but individualized-anticoagulation resumption in selected high-risk patients, pending prospective validation."

Journal • Retrospective data • Cardiovascular • Hematological Disorders • Ischemic stroke

Surgical excision of cerebral glioma and multimodal treatment including Cerebrolysin: a case report. (PubMed, J Med Life) - "Clinically, patients may present with headache, nausea, vomiting, seizures, or subtle cognitive and motor deficits, progressing in severe cases to deterioration of consciousness. Incorporating cerebroprotective interventions in perioperative management represents a promising approach to enhance recovery, functional independence, and quality of life in neurosurgical oncology patients."

Journal • Brain Cancer • Cardiovascular • CNS Disorders • Epilepsy • Glioma • Hypertension • Oncology • Pain • Solid Tumor

Use of nootropics in Alzheimer's disease: An analysis of regulatory positions and drug policies in the countries of the Commonwealth of Independent States. (PubMed, Int J Risk Saf Med) - "We compared the results of Russia with other countries regulatory and policy positions.ResultsE-Library searches identified 11 nootropicspiracetam, citicoline, idebenone, vinpocetine, choline alfoscerate, Cerebrolysin®, Kortexin®, ethylmethylhydroxypyridine succinate, glycine, nicergoline, nimodipine. Eight nootropic have registration for use in all CIS countries (excluding idebenone, nimodipine), four (piracetam, nimodipine, nicergoline, idebenone) - in UK, nimodipine - in the USA, and idebenone - in EU...None is included on the WHO Model EML and the National EML of Kyrgyzstan, Only CPG of the RF recommend using two nootropics as adjuvant therapy of Alzheimer's disease, Cerebrolysin® and choline alfoscerate. CPG of the European Union, the United Kingdom, and the USA do not mention nootropics as potential treatment options for Alzheimer's disease."

Journal • Alzheimer's Disease • CNS Disorders • Dementia

Cerebrolysin Ameliorates Age-Induced Dendritic Spine Degeneration and Memory Decline in C57BL6 Mice. (PubMed, Neurochem Res) - "This study provides the first integrated demonstration that CBL enhances dendritic spine maturation and dendritic structural remodeling while concurrently improving cognitive outcomes within the same cohort of aged animals. Collectively, our findings position CBL as a promising therapeutic candidate to counteract age-related synaptic loss and cognitive decline, advancing current understanding of neuroprotective interventions in aging."

Journal • Preclinical • SYP

Combined citicoline and Cerebrolysin for neuroprotection in traumatic brain injury: a retrospective cohort analysis. (PubMed, Front Neurol) - "Combined treatment with citicoline and Cerebrolysin may offer additional benefits for neurological recovery in patients with severe traumatic brain injury. Although statistical significance was not reached, the observed trend supports the need for further prospective, controlled studies to explore potential therapeutic advantages."

Journal • Retrospective data • CNS Disorders • Critical care • Inflammation • Vascular Neurology

Delta power surge and alpha power decline in traumatic brain injury recovery: A quantitative EEG analysis of the CAPTAIN-rTMS trial. (PubMed, J Clin Transl Sci) - "Both repetitive transcranial magnetic stimulation (rTMS) and Cerebrolysin (CRB) are promising therapies regulating neural plasticity...We found overall slowing of brain electrical activity during recovery after TBI, which was further influenced by rTMS and CRB treatment. Resting-state relative power spectral densities correlate with neuropsychological measurements."

Journal • CNS Disorders • Vascular Neurology

Retraction Note: Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure. (PubMed, BMC Neurosci) - No abstract available

Journal

Cerebroprotection in acute ischemic stroke: Perspectives on Combining Cerebrolysin with Recanalization Therapy. (PubMed, J Stroke Cerebrovasc Dis) - "The CERECAP program has generated compelling data demonstrating Cerebrolysin's alignment with current AIS reperfusion therapy concepts, particularly its role in early intervention targeting multiple pathways. We review these studies and discuss the critical need to clearly define the patient population that benefit most from adjunctive Cerebrolysin therapy in AIS."

Journal • Cardiovascular • Hematological Disorders • Ischemic stroke

Cerebrolysin ameliorates ketamine-mediated anxiety and cognitive impairments via modulation of mitochondrial function and CREB/PGC-1α pathway. (PubMed, Mol Brain) - "Furthermore, CBL therapy upregulated the hippocampal expression of the proteins CREB, p-CREB, and PGC-1α compared with the ketamine-treated animals. It is speculated that treatment with CBL can attenuate ketamine-induced cognitive deficits and anxiety-like behaviors through the upregulation of the CREB/PGC-1α pathway and the improvement of mitochondrial function."

Journal • CNS Disorders • Cognitive Disorders • Mental Retardation • Mood Disorders • Psychiatry • Schizophrenia

Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU (clinicaltrials.gov) - P3 | N=150 | Completed | Sponsor: Ain Shams University | Trial primary completion date: Mar 2025 ➔ May 2025 | Recruiting ➔ Completed

Trial completion • Trial primary completion date • CNS Disorders • Hematological Disorders • Vascular Neurology

Comparative effects of Cerebrolysin and Erythropoietin in dendritic spines and memory in an animal model of aging (Neuroscience 2025) - "In these groups, a recovery in the proportion of mushroom spines and a decrease in stubby spines were observed, suggesting maintenance of functional synaptic properties. These findings support the therapeutic potential of CBL and EPO in the prevention and treatment of structural and functional alterations associated with brain aging."

Preclinical • CNS Disorders

Therapeutic strategies in vascular cognitive impairment: A systematic review and meta-analysis. (PubMed, Alzheimers Dement) - "Considerable methodological heterogeneity across VCI trials undermined the strength of evidence for both positive and negative findings, ultimately decreasing confidence in the possibility of treating VCI. Ginkgo biloba extracts have shown the greatest cognitive and functional benefits, though their clinical significance remains uncertain, and certainty of evidence is overall low. Future trials should focus on a single VCI subtype, prioritize interventions with a strong mechanistic rationale, standardize diagnostic criteria, ensure adequate power for chosen outcomes, test against placebo, and implement FAIR data sharing to accelerate therapeutic discovery."

Clinical • Journal • Retrospective data • Review • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Vascular Neurology

Cerebrolysin treatment in a case of post-herpes simplex encephalitis with neuropsychiatric symptoms. (PubMed, J Med Life) - "The patient was treated with acyclovir and dexamethasone in the acute phase, followed by Cerebrolysin administration in the post-acute phase. This case highlights the potential therapeutic role of Cerebrolysin in managing post-encephalitic cognitive dysfunction, underscoring the need for further studies."

Journal • CNS Disorders • Cognitive Disorders • Epilepsy • Herpes Simplex • Infectious Disease • Psychiatry

Safety and feasibility of cerebrolysin in treatment of primary intracerebral hemorrhage (CLINCH)-a prospective, randomized, open-label, blinded endpoint pilot trial. (PubMed, Front Neurol) - "The restrictive eligibility criteria may limit generalizability but enhance the likelihood of detecting treatment effects. If positive, results would support a larger confirmatory trial and inform the sample size."

Journal • Cardiovascular • Cerebral Hemorrhage • Hematological Disorders • Ischemic stroke

EFFICACY OF CEREBROLYSIN TREATMENT AS AN ADD-ON THERAPY TO MECHANICAL THROMBECTOMY IN PATIENTS WITH ACUTE ISCHEMIC STROKE: FINAL RESULTS OF A PROSPECTIVE, OPEN LABEL STUDY. (WSC 2025) - "Cerebrolysin improved functional outcomes at 90 days and 12 months, accelerated neurological recovery, and reduced complications post-MT in patients with small ischemic core, good collateral circulation and effective recanalization at baseline. These findings warrant further evaluation in randomized trials."

Clinical • Cardiovascular • Diabetes • Ischemic stroke • Metabolic Disorders